Eosinophilic Gastritis or Gastroenteritis – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030
Eosinophilic
esophagitis is the most commonly recognized EDD. Patients often present with
symptoms similar to gastroesophageal reflux disease; however, they are not
responsive to traditional antireflux therapy. In fact, there is emerging data
to suggest that the use of acid-suppressive medications may predispose patients
to the development of eosinophilic esophagitis. The alteration of gastric pH
caused by antisecretory medications has been shown to affect protein digestion,
allowing a larger percentage of ingested protein to be absorbed in larger
fragments, potentially inducing an immunologic response. The diagnosis of
eosinophilic esophagitis relies on endoscopic biopsy. Visualization of the
esophagus during endoscopy may appear abnormal, including esophageal furrows
and strictures, white plaques, or mucosal rings. However, in one-third of
patients, the appearance of the esophagus may be normal.
The
reported incidence is approximately 6.5 to 7.8 cases per 100,000 population.
However, increased awareness of the disease over the past several years has led
to an increasing number of cases identified.
The competitive
landscape of Eosinophilic Gastritis or Gastroenteritis includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Eosinophilic
Gastritis or Gastroenteritis across 8 MM market from the centre of Excellence/
Public/ Private hospitals participated in the study. Insights around current
treatment landscape, epidemiology, clinical characteristics, future treatment
paradigm, and Unmet needs.
Eosinophilic
Gastritis or Gastroenteritis Market
Forecast: Patient Based Forecast Model (MS. Excel Based Automated
Dashboard) which Data Inputs with sourcing, Market Event, and Product Event,
Country specific Forecast Model, Market uptake and patient share uptake,
Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario,
Summary, and Insights.
S. No Asset Company Stage
1 AK002 Allakos, Inc. Phase 3
2 CC-93538 Celgene Phase 3
3 APT-1011 Ellodi
Pharmaceuticals, LP Phase 3
4 reslizumab Ception
Therapeutics Phase 3
5 Dupilumab Regeneron
Pharmaceuticals Phase 2
6 ESO-101 EsoCap
AG Phase 2
7 Reslizumab Ception
Therapeutics Phase 3
8 Benralizumab AstraZeneca Phase 3
9 Etrasimod Arena
Pharmaceuticals Phase 2
10 budesonide Takeda Phase 2
Continued
Comments
Post a Comment